Australia markets closed

Celyad Oncology SA (CLYYF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.35800.0000 (0.00%)
At close: 09:30AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 14.64M
Enterprise value 9.88M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)171.62
Price/book (mrq)13.61
Enterprise value/revenue 224.62
Enterprise value/EBITDA -0.32

Trading information

Stock price history

Beta (5Y monthly) 1.30
52-week change 3-92.30%
S&P500 52-week change 324.19%
52-week high 34.6500
52-week low 30.3580
50-day moving average 30.3840
200-day moving average 30.5061

Share statistics

Avg vol (3-month) 354
Avg vol (10-day) 3N/A
Shares outstanding 541.43M
Implied shares outstanding 641.59M
Float 811.86M
% held by insiders 17.63%
% held by institutions 135.50%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-8,110.35%

Management effectiveness

Return on assets (ttm)-33.03%
Return on equity (ttm)-159.08%

Income statement

Revenue (ttm)102k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -9M
Net income avi to common (ttm)-8.45M
Diluted EPS (ttm)-1.4500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7M
Total cash per share (mrq)0.17
Total debt (mrq)1.06M
Total debt/equity (mrq)16.78%
Current ratio (mrq)3.79
Book value per share (mrq)0.15

Cash flow statement

Operating cash flow (ttm)-15.2M
Levered free cash flow (ttm)-14.45M